SUPERNUS PHARMACEUTICALS, INC. (SUPN) Stock
2 members of Congress disclosed 9 trades in SUPN since 2020: 7 purchases and 2 sales, most recently Gilbert Cisneros (purchase, Mar 3, 2026). 4 of the hedge funds AlphaScala tracks reported SUPN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $179.21M.
Which members of Congress traded SUPERNUS PHARMACEUTICALS, INC. (SUPN)?
Most recent: Gilbert Cisneros (purchase, Mar 3, 2026); records start May 28, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-11 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-10-09 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-03-24 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2022-12-23 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-11-13 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-07-17 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-06-01 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all SUPN political trades →Which hedge funds own SUPN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.85M | $179.21M | +16% |
| Renaissance Technologies Jim Simons (founder) | 1.48M | $68.75M | -13% |
| Citadel Ken Griffin | 1.37M | $63.90M | -8% |
| D.E. Shaw David Shaw | 768K | $35.70M | +23% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →SUPN price chart
Powered by TradingViewWhat does SUPERNUS PHARMACEUTICALS, INC. do?
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its primary function is to innovate therapeutic solutions that address unmet medical needs in neurology and psychiatry. Known for its robust research and development efforts, Supernus has a portfolio that includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), and bipolar disorder. The company's significant contributions to the CNS field have made it a notable entity in the pharmaceutical industry. Supernus operates through a combination of proprietary products and strategic partnerships, ensuring a steady pipeline of new medications. This focus on CNS disorders highlights its specialization within healthcare, impacting patient lives by improving management and treatment of these conditions. Supernus Pharmaceuticals' market significance is underscored by its dedication to enhancing the quality of life for patients through advanced, targeted therapies. By leveraging extensive research, clinical trials, and regulatory expertise, Supernus continues to play an important role in the pharmaceutical sector's innovation landscape.